As TNNT1 pathogenic variants have impacts on both slow and fast twitch muscle fibres, our findings emphasize that a combination of mavacamten and fast myosin inhibitor may be considered the preferential choices for TNNT1‐related congenital myopathies. Here, MYH14 is linked to congenital myopathy.